Scholarlink

Aims/hypothesis <p>Lactation is associated with reduced maternal risk of future diabetes mellitus and cardiovascular disease. Human milk oligosaccharides (HMOs), bioactive glycans produced in the mammary gland and already detectable in the maternal circulation during pregnancy, are hypothesised to exert endocrine and metabolic effects. We investigated circulating HMOs in the postpartum period, and assessed their short-term modulation by glucose and insulin, and the relationship between plasma and milk HMO profiles.</p> Methods <p>At 5–7 weeks postpartum, 28 women (16 with prior gestational diabetes [GDM]; 18 who were breastfeeding) underwent both a 75&#xa0;g oral glucose tolerance test (OGTT) and a hyperinsulinaemic–euglycaemic clamp. HMOs were quantified in plasma and milk using HPLC.</p> Results <p>Seventeen HMOs were detected in milk, of which six were also detected in plasma at concentrations that were approximately 10,000-fold lower but were highly correlated across the two compartments. The lactosamine-based glycans 3′-sialyllactosamine (3′SLN) and 6′-sialyllactosamine (6′SLN) were only found in plasma. Lactation status had no significant impact on plasma HMO levels, except for a lower 6′SLN level in breastfeeding women. Women with prior GDM showed lower HMO concentrations in milk when fasting. Plasma HMOs exhibited short-term changes during both tests: during the OGTT, the levels of the fucosylated HMOs 2′-fucosyllactose (2′FL), lacto-<i>N</i>-fucopentaose&#xa0;1 (LNFP1) and lacto-<i>N</i>-difucohexaose (LNDFH) significantly decreased, while that of 3′-sialyllactose (3′SL) increased; during the clamp, the levels of all fucosylated HMOs and 3′SL declined, whereas that of 3′SLN increased with rising insulin levels. In milk, only the levels of 2′FL and lactodifucotetraose (LDFT) decreased significantly during the clamp. During the clamp, the area under the curve (AUC) of plasma oligosaccharides partly correlated with BMI and metabolic clearance rate.</p> Conclusions/interpretation <p>Circulating HMOs persist during lactation and are acutely regulated by glucose and insulin. The differential response of fucosylated and sialylated species suggests metabolic regulation of HMO biosynthesis, secretion or clearance. These findings support the concept of HMOs as candidate signal molecules in maternal metabolism, linking lactation with postpartum metabolic adaptation.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Short-term modulation of human milk oligosaccharides in plasma and milk by glucose and insulin: insights into postpartum metabolic regulation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Lukas Schönbacher,
  • Anna M. Walzl,
  • Christina Stern,
  • Harald C. Köfeler,
  • Harald Sourij,
  • Herbert Fluhr,
  • Evelyn Jantscher-Krenn,
  • Maria A. Ramos-Roman

摘要

Aims/hypothesis

Lactation is associated with reduced maternal risk of future diabetes mellitus and cardiovascular disease. Human milk oligosaccharides (HMOs), bioactive glycans produced in the mammary gland and already detectable in the maternal circulation during pregnancy, are hypothesised to exert endocrine and metabolic effects. We investigated circulating HMOs in the postpartum period, and assessed their short-term modulation by glucose and insulin, and the relationship between plasma and milk HMO profiles.

Methods

At 5–7 weeks postpartum, 28 women (16 with prior gestational diabetes [GDM]; 18 who were breastfeeding) underwent both a 75 g oral glucose tolerance test (OGTT) and a hyperinsulinaemic–euglycaemic clamp. HMOs were quantified in plasma and milk using HPLC.

Results

Seventeen HMOs were detected in milk, of which six were also detected in plasma at concentrations that were approximately 10,000-fold lower but were highly correlated across the two compartments. The lactosamine-based glycans 3′-sialyllactosamine (3′SLN) and 6′-sialyllactosamine (6′SLN) were only found in plasma. Lactation status had no significant impact on plasma HMO levels, except for a lower 6′SLN level in breastfeeding women. Women with prior GDM showed lower HMO concentrations in milk when fasting. Plasma HMOs exhibited short-term changes during both tests: during the OGTT, the levels of the fucosylated HMOs 2′-fucosyllactose (2′FL), lacto-N-fucopentaose 1 (LNFP1) and lacto-N-difucohexaose (LNDFH) significantly decreased, while that of 3′-sialyllactose (3′SL) increased; during the clamp, the levels of all fucosylated HMOs and 3′SL declined, whereas that of 3′SLN increased with rising insulin levels. In milk, only the levels of 2′FL and lactodifucotetraose (LDFT) decreased significantly during the clamp. During the clamp, the area under the curve (AUC) of plasma oligosaccharides partly correlated with BMI and metabolic clearance rate.

Conclusions/interpretation

Circulating HMOs persist during lactation and are acutely regulated by glucose and insulin. The differential response of fucosylated and sialylated species suggests metabolic regulation of HMO biosynthesis, secretion or clearance. These findings support the concept of HMOs as candidate signal molecules in maternal metabolism, linking lactation with postpartum metabolic adaptation.

Graphical Abstract